Member Info for Rocket79

This multibags in coming months

💥 Desperate need by patients

💥 Health care systems desperately need to reduce spending

💥 FDA and Madicare approved

💥 Tempus AI deal for US rollout

💥 Only FDA approved test of its kind

💥 Massive barriers to entry

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

15p is only a very short term target.

For real investors with patience this could be 100p+

R&D time is over, done, complete, doesnt require much capital now, its time to print money now $$$, Tempus Ai will open those doors.

There's a need and a must here. Do you spend $950 on a test, or potentially wasting $100k per patient per year on dialysis which is not required. Well the answer from every single perspective is easy to answer.

THIS TEST IS A MUST. IT'S A NECESSITY.

All about spreading the word and gaining access to clinicians.

Now seller cleared this will rerate. That was what dropped us back from 15p on the collaboration news. Polar Capital have 3 working days to inform change of holdings. Good luck all

The partnership with Tempus is a game-changer for Renalytix because it provides a massive, pre-built distribution network for its KidneyIntelX.dkd test. This collaboration gives Renalytix immediate access to Tempus's network of over 2,000 healthcare institutions, eliminating the need to build a costly sales team.

​By integrating the test into Tempus's AI platform, which is already used by doctors, the partnership simplifies the ordering process and accelerates market adoption. This strategic move is expected to significantly boost the volume of tests sold, paving the way for substantial revenue growth and long-term commercial success for Renalytix.

With an FDA-approved and Medicare-reimbursed test in a large and underserved market, the collaboration could be a game-changer for Renalytix's commercial growth and long-term financial performance.

15p is only a very short term target.

For real investors with patience this could be 100p+

R&D time is over, done, complete, doesnt require much capital now, its time to print money now $$$, Tempus Ai will open those doors.

There's a need and a must here. Do you spend $950 on a test, or potentially wasting $100k per patient per year on dialysis which is not required. Well the answer from every single perspective is easy to answer.

THIS TEST IS A MUST. IT'S A NECESSITY.

All about spreading the word and gaining access to clinicians.

There is no need for placing. As been shown we are funded to breakeven. Can we just ignore the deramper and don't use their thread as it suit ls there agenda

Nice try they don't need funds.

Not sure why the panic here, just have some patience - overhangs take time to churn

and for those worried about funding - do some research before buying:

As per audited results:

"The Company has now largely completed its reorganization from development activities to commercial sales, and has implemented a new large customer launch of kidneyintelX.dkd post-period end. With growing commercial adoption, significantly lower operating expenses, an 80% reduction of outstanding debt obligations, and an £11.8m funding closed on 4 November 2024, Renalytix is funded and projected to deliver anticipated profitability in two years with no further funding requirements."

This is a billion $ company in the making and have just partnered a $15bn USD AI co

This multibags in coming months

💥 Desperate need by patients

💥 Health care systems desperately need to reduce spending

💥 FDA and Madicare approved

💥 Tempus AI deal for US rollout

💥 Only FDA approved test of its kind

💥 Massive barriers to entry

Hold don't sell they want our shares. This os glong to multibag

This multibags in coming months

💥 Desperate need by patients

💥 Health care systems desperately need to reduce spending

💥 FDA and Madicare approved

💥 Tempus AI deal for US rollout

💥 Only FDA approved test of its kind

💥 Massive barriers to entry

The market is giving us a gift at this price. News on collaboration not priced in at all. This will turn and rerate.

Thisbis exactly why the share price went to 15p on the mews of the collaboration. The only thing that pulled it back was the seller. They must be finished so we will reach 15p easily in coming sessions imo

​Tempus AI primarily operates in the United States, where it has a significant presence with numerous offices and labs. The company works with a large number of hospitals, institutions, and pharmaceutical companies across the country.

​Beyond the U.S., Tempus has been expanding its international operations. Key international markets where it has established a presence or partnerships include:

​Japan: Tempus formed a joint venture with SoftBank in Japan called SB Tempus to provide precision medicine services in the country.

​Canada: Tempus has an office in Calgary, Canada.

​United Kingdom: The company has an office in London, UK, to support its European operations.

Https://m.youtube.com/watch?v=Mdvnf7qS464

Brilliant video from 9 months ago with the Chairman.

Shows the enormous opportunity here now Tempus can unlock it.

Recommend watch only 14min. They are fully funded to breakeven. I bought more after watching. Good luck

https://www.youtube.com/watch?v=Mdvnf7qS464

Posted earlier. Not mine.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

It's not ramping we know reason for drop. Seller must be cleared or almost. Company funed to cash flow break even. So funds not required. The collaboration is not priced in at all. DYOR

Massively undervalued. Collaboration not priced in at all even at 15p. Won't stay this low for long. Buy